Leitlinie|Version|Jahr|Author|Inhaltstyp|Position|Referenz|Link
Multiples Myelom|1.0|2022|Einsele, Hermann|Hintergrund||Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384 (8):705-716|https://pubmed.ncbi.nlm.nih.gov/33626253/
Multiples Myelom|1.0|2022|Goldschmidt, Hartmut|Hintergrund||Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384 (8):705-716|https://pubmed.ncbi.nlm.nih.gov/33626253/
Multiples Myelom|1.0|2022|Weisel, Katja|Hintergrund||Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384 (8):705-716|https://pubmed.ncbi.nlm.nih.gov/33626253/
Multiples Myelom|1.0|2022|Weisel, Katja|Hintergrund||Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21 (2):207-221|https://pubmed.ncbi.nlm.nih.gov/31859245/
Multiples Myelom|1.0|2022|Knop, Stefan|Hintergrund||Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395 (10218):132-141|https://pubmed.ncbi.nlm.nih.gov/31836199/
Multiples Myelom|1.0|2022|Goldschmidt, Hartmut|Hintergrund||Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; ():|https://pubmed.ncbi.nlm.nih.gov/34655533/
Multiples Myelom|1.0|2022|Weisel, Katja|Hintergrund||Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; ():|https://pubmed.ncbi.nlm.nih.gov/34655533/
Multiples Myelom|1.0|2022|Einsele, Hermann|Hintergrund|LETZTAUTOR|Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019;33 (11):2710-2719|https://pubmed.ncbi.nlm.nih.gov/31462732/
Multiples Myelom|1.0|2022|Engelhardt, Monika|Hintergrund||Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019;33 (11):2710-2719|https://pubmed.ncbi.nlm.nih.gov/31462732/
Multiples Myelom|1.0|2022|Knop, Stefan|Hintergrund|ERSTAUTOR|Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019;33 (11):2710-2719|https://pubmed.ncbi.nlm.nih.gov/31462732/
Multiples Myelom|1.0|2022|Weisel, Katja|Hintergrund||Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396 (10245):186-197|https://pubmed.ncbi.nlm.nih.gov/32682484/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund|ERSTAUTOR|Dührsen U. Therapy-induced leukemia - an underestimated complication of antineoplastic chemotherapy?. Zentralbl Gynakol. 2005;127:235-41|https://pubmed.ncbi.nlm.nih.gov/16037905/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund|ERSTAUTOR|Dührsen U, Deppermann KM, Pox C, Holstege A. Evidence-based follow-up for adults with cancer. Dtsch Arztebl Int. 2019;116:663-9|https://pubmed.ncbi.nlm.nih.gov/31658935/
DLBCL|1.0|2022|Blödt, Susanne|Hintergrund|ERSTAUTOR|Blödt S, Mittring N, Schützler L, Fischer F, Holmberg C, Horneber M, et al. A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study. BMC Cancer. 2016;16:843|https://pubmed.ncbi.nlm.nih.gov/27809814/
DLBCL|1.0|2022|Horneber, Markus|Hintergrund||Blödt S, Mittring N, Schützler L, Fischer F, Holmberg C, Horneber M, et al. A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study. BMC Cancer. 2016;16:843|https://pubmed.ncbi.nlm.nih.gov/27809814/
DLBCL|1.0|2022|Horneber, Markus|Hintergrund|LETZTAUTOR|Güthlin C, Bartsch HH, Joos S, Längler A, Lampert C, Ritter C, et al. KOKON: A Germany-wide collaborative research project to identify needs, provide information, foster communication and support decision-making about complementary and alternative medicine in oncology. Complement Med Res. 2020;27:105-11|https://pubmed.ncbi.nlm.nih.gov/31722354/
DLBCL|1.0|2022|Horneber, Markus|Hintergrund|ERSTAUTOR|Horneber M, van Ackeren G, Fischer F, Kappauf H, Birkmann J. Addressing Unmet Information Needs: Results of a Clinician-Led Consultation Service About Complementary and Alternative Medicine for Cancer Patients and Their Relatives. Integr Cancer Ther. 2018;17:1172-82|https://pubmed.ncbi.nlm.nih.gov/30352519/
DLBCL|1.0|2022|Skoetz, Nicole|Hintergrund|LETZTAUTOR|Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N. Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev. 2019;1:CD009075|https://pubmed.ncbi.nlm.nih.gov/30702150/
DLBCL|1.0|2022|Rieger, Christina|Hintergrund|LETZTAUTOR|Christopeit M, Rieger C. Vakzinierung gegen die saisonale Influenza unter oder nach der Therapie mit Anti-CD20-Antikorpern - Stellungname vom 2.11.2020. . 2020;Online:|https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/grippeschutzimpfung_anti-cd20-antikoerper/agiho_vakzinierung_saisonale_influenza_anti_b_zell_20201031.pdf
DLBCL|1.0|2022|Herfarth, Klaus|Hintergrund|LETZTAUTOR|König L, Bougatf N, Hörner-Rieber J, Chaudhri N, Mielke T, Klüter S, et al. Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. Strahlenther Onkol. 2019;195:677-87|https://pubmed.ncbi.nlm.nih.gov/30972453/
DLBCL|1.0|2022|Eich, Hans-Theodor|Empfehlung||Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/
DLBCL|1.0|2022|Eich, Hans-Theodor|Hintergrund||Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/
DLBCL|1.0|2022|Schmidberger, Heinz|Empfehlung||Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/
DLBCL|1.0|2022|Schmidberger, Heinz|Hintergrund||Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/
DLBCL|1.0|2022|Schöning, Tilman|Hintergrund||Rohlfing S, Aurich M, Schöning T, Ho AD, Witzens-Harig M. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases. Clin Lymphoma Myeloma Leuk. 2015;15:458-63|https://pubmed.ncbi.nlm.nih.gov/25899891/
DLBCL|1.0|2022|Borchmann, Peter|Empfehlung||Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250-9|https://pubmed.ncbi.nlm.nih.gov/23168367/
DLBCL|1.0|2022|Borchmann, Peter|Hintergrund||Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250-9|https://pubmed.ncbi.nlm.nih.gov/23168367/
DLBCL|1.0|2022|Borchmann, Peter|Empfehlung||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Borchmann, Peter|Hintergrund||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Frontzek, Fabian|Empfehlung|ERSTAUTOR|Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Frontzek, Fabian|Hintergrund|ERSTAUTOR|Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Held, Gerhard|Empfehlung||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Lenz, Georg|Empfehlung||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Lenz, Georg|Hintergrund||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Ott, German|Empfehlung||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Ott, German|Hintergrund||Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/
DLBCL|1.0|2022|Friedrichs, Birte|Hintergrund|ERSTAUTOR|Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2019;184:760-8|https://pubmed.ncbi.nlm.nih.gov/30520013/
DLBCL|1.0|2022|Lenz, Georg|Hintergrund||Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2019;184:760-8|https://pubmed.ncbi.nlm.nih.gov/30520013/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund|LETZTAUTOR|Hüttmann A, Müller S, Jöckel KH, Dührsen U. Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:e488-9; author reply e490-1|https://pubmed.ncbi.nlm.nih.gov/20644097/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund|ERSTAUTOR|Hüttmann A, Müller S, Jöckel KH, Dührsen U. Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:e488-9; author reply e490-1|https://pubmed.ncbi.nlm.nih.gov/20644097/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund|LETZTAUTOR|Rekowski J, Hüttmann A, Schmitz C, Müller SP, Kurch L, Kotzerke J, et al. Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: Comparison of the Deauville 5-Point Scale and the SUV. J Nucl Med. 2021;62:37-42|https://pubmed.ncbi.nlm.nih.gov/32385164/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund||Rekowski J, Hüttmann A, Schmitz C, Müller SP, Kurch L, Kotzerke J, et al. Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: Comparison of the Deauville 5-Point Scale and the SUV. J Nucl Med. 2021;62:37-42|https://pubmed.ncbi.nlm.nih.gov/32385164/
DLBCL|1.0|2022|Dührsen, Ulrich|Empfehlung|ERSTAUTOR|Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024-34|https://pubmed.ncbi.nlm.nih.gov/29750632/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund|ERSTAUTOR|Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024-34|https://pubmed.ncbi.nlm.nih.gov/29750632/
DLBCL|1.0|2022|Hüttmann, Andreas|Empfehlung|LETZTAUTOR|Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024-34|https://pubmed.ncbi.nlm.nih.gov/29750632/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund|LETZTAUTOR|Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024-34|https://pubmed.ncbi.nlm.nih.gov/29750632/
DLBCL|1.0|2022|Klapper, Wolfram|Empfehlung||Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024-34|https://pubmed.ncbi.nlm.nih.gov/29750632/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024-34|https://pubmed.ncbi.nlm.nih.gov/29750632/
DLBCL|1.0|2022|Dührsen, Ulrich|Empfehlung|LETZTAUTOR|Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019;98:897-907|https://pubmed.ncbi.nlm.nih.gov/30610279/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund|LETZTAUTOR|Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019;98:897-907|https://pubmed.ncbi.nlm.nih.gov/30610279/
DLBCL|1.0|2022|Hüttmann, Andreas|Empfehlung|ERSTAUTOR|Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019;98:897-907|https://pubmed.ncbi.nlm.nih.gov/30610279/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund|ERSTAUTOR|Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019;98:897-907|https://pubmed.ncbi.nlm.nih.gov/30610279/
DLBCL|1.0|2022|Klapper, Wolfram|Empfehlung||Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019;98:897-907|https://pubmed.ncbi.nlm.nih.gov/30610279/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. Ann Hematol. 2019;98:897-907|https://pubmed.ncbi.nlm.nih.gov/30610279/
DLBCL|1.0|2022|Dietlein, Markus|Hintergrund||Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-8|https://pubmed.ncbi.nlm.nih.gov/17242397/
DLBCL|1.0|2022|Oertel, Michael|Hintergrund||Pepper NB, Oertel M, Kittel C, Kröger KJ, Elsayad K, Haverkamp U, et al. Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma. Strahlenther Onkol. 2021;197:56-62|https://pubmed.ncbi.nlm.nih.gov/32945894/
DLBCL|1.0|2022|Chapuy, Björn|Hintergrund||Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3Ka/d is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70-80|https://pubmed.ncbi.nlm.nih.gov/30322870/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, et al. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019;37:3359-68|https://pubmed.ncbi.nlm.nih.gov/31498031/
DLBCL|1.0|2022|Berdel, Christian|Hintergrund||Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:|
DLBCL|1.0|2022|Borchmann, Peter|Hintergrund||Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:|
DLBCL|1.0|2022|Held, Gerhard|Hintergrund|ERSTAUTOR|Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:|
DLBCL|1.0|2022|Ott, German|Hintergrund||Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:|
DLBCL|1.0|2022|Thurner, Lorenz|Hintergrund||Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:|
DLBCL|1.0|2022|Chapuy, Björn|Hintergrund|ERSTAUTOR|Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019;134:2369-82|https://pubmed.ncbi.nlm.nih.gov/31697821/
DLBCL|1.0|2022|Ott, German|Hintergrund||Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-62|https://pubmed.ncbi.nlm.nih.gov/12975453/
DLBCL|1.0|2022|Ott, German|Hintergrund||Yuan J, Wright G, Rosenwald A, Steidl C, Gascoyne RD, Connors JM, et al. Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling. Am J Surg Pathol. 2015;39:1322-30|https://pubmed.ncbi.nlm.nih.gov/26135560/
DLBCL|1.0|2022|Chapuy, Björn|Hintergrund|ERSTAUTOR|Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869-81|https://pubmed.ncbi.nlm.nih.gov/26702065/
DLBCL|1.0|2022|Chapuy, Björn|Hintergrund|ERSTAUTOR|Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679-90|https://pubmed.ncbi.nlm.nih.gov/29713087/
DLBCL|1.0|2022|Ott, German|Hintergrund||Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679-90|https://pubmed.ncbi.nlm.nih.gov/29713087/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679-90|https://pubmed.ncbi.nlm.nih.gov/29713087/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund|ERSTAUTOR|Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31:4115-22|https://pubmed.ncbi.nlm.nih.gov/24062391/
DLBCL|1.0|2022|Rübe, Christian|Hintergrund||Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31:4115-22|https://pubmed.ncbi.nlm.nih.gov/24062391/
DLBCL|1.0|2022|Rübe, Christian|Hintergrund||Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19:3861-73|https://pubmed.ncbi.nlm.nih.gov/11559724/
DLBCL|1.0|2022|Rübe, Christian|Hintergrund||Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19:3874-83|https://pubmed.ncbi.nlm.nih.gov/11559725/
DLBCL|1.0|2022|Liersch, Rüdiger|Hintergrund||Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005;23:7050-9|https://pubmed.ncbi.nlm.nih.gov/16129843/
DLBCL|1.0|2022|Ott, German|Hintergrund|LETZTAUTOR|Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96:1327-34|https://pubmed.ncbi.nlm.nih.gov/21659362/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund|LETZTAUTOR|Johl A, Lengfelder E, Hiddemann W, Klapper W. Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel. Ann Hematol. 2016;95:1281-6|https://pubmed.ncbi.nlm.nih.gov/27236576/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund|ERSTAUTOR|Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol. 2007;25:3330-6|https://pubmed.ncbi.nlm.nih.gov/17664481/
DLBCL|1.0|2022|Ott, German|Hintergrund|LETZTAUTOR|Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol. 2007;25:3330-6|https://pubmed.ncbi.nlm.nih.gov/17664481/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund|LETZTAUTOR|Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323-9|https://pubmed.ncbi.nlm.nih.gov/27117536/
DLBCL|1.0|2022|Ott, German|Hintergrund||Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323-9|https://pubmed.ncbi.nlm.nih.gov/27117536/
DLBCL|1.0|2022|Pöschel, Viola|Hintergrund||Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323-9|https://pubmed.ncbi.nlm.nih.gov/27117536/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323-9|https://pubmed.ncbi.nlm.nih.gov/27117536/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, et al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia. 2016;30:854-60|https://pubmed.ncbi.nlm.nih.gov/26621338/
DLBCL|1.0|2022|Ott, German|Hintergrund||Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, et al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia. 2016;30:854-60|https://pubmed.ncbi.nlm.nih.gov/26621338/
DLBCL|1.0|2022|Ott, German|Hintergrund||King RL, Goodlad JR, Calaminici M, Dotlic S, Montes-Moreno S, Oschlies I, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020;476:647-65|https://pubmed.ncbi.nlm.nih.gov/31863183/
DLBCL|1.0|2022|Liersch, Rüdiger|Hintergrund||Pohlen M, Gerth HU, Liersch R, Koschmieder S, Mesters RM, Kessler T, et al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. Am J Hematol. 2011;86:E61-4|https://pubmed.ncbi.nlm.nih.gov/21898532/
DLBCL|1.0|2022|Borchmann, Peter|Hintergrund||Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56|https://pubmed.ncbi.nlm.nih.gov/30501490/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Pfreundschuh MG, Trümper L, Ma D, Österborg A, Pettengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. . 2004;22:6500|
DLBCL|1.0|2022|Glaß, Bertram|Hintergrund|LETZTAUTOR|Held G, Glaß B. Diffuses grosszelliges B-Zell Lymphom: Primar- und Rezidivtherapie. . 2019;:880-91|
DLBCL|1.0|2022|Held, Gerhard|Hintergrund|ERSTAUTOR|Held G, Glaß B. Diffuses grosszelliges B-Zell Lymphom: Primar- und Rezidivtherapie. . 2019;:880-91|
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund||Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36:2845-53|https://pubmed.ncbi.nlm.nih.gov/ 30125215/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund||Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36:2845-53|https://pubmed.ncbi.nlm.nih.gov/ 30125215/
DLBCL|1.0|2022|Frontzek, Fabian|Hintergrund|LETZTAUTOR|Schmitz N, Frontzek F. CNS prophylaxis in DLBCL: Time to say goodbye?. Blood. 2022;139:315-7|https://pubmed.ncbi.nlm.nih.gov/35050332/
DLBCL|1.0|2022|Borchmann, Peter|Hintergrund||Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line Tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2021;Online ahead of print:|https://pubmed.ncbi.nlm.nih.gov/34904798/
DLBCL|1.0|2022|Chapuy, Björn|Hintergrund||Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:5183|https://pubmed.ncbi.nlm.nih.gov/34465776/
DLBCL|1.0|2022|Frontzek, Fabian|Hintergrund|ERSTAUTOR|Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:5183|https://pubmed.ncbi.nlm.nih.gov/34465776/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:5183|https://pubmed.ncbi.nlm.nih.gov/34465776/
DLBCL|1.0|2022|Lenz, Georg|Hintergrund|LETZTAUTOR|Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:5183|https://pubmed.ncbi.nlm.nih.gov/34465776/
DLBCL|1.0|2022|Ott, German|Hintergrund||Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:5183|https://pubmed.ncbi.nlm.nih.gov/34465776/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund||Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52:216-21|https://pubmed.ncbi.nlm.nih.gov/27643872/
DLBCL|1.0|2022|Gerlach, Christina|Hintergrund|ERSTAUTOR|Gerlach C, Alt-Epping B, Oechsle K. Specific challenges in end-of-life care for patients with hematological malignancies. Curr Opin Support Palliat Care. 2019;13:369-79|https://pubmed.ncbi.nlm.nih.gov/31644451/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017;35:2515-26|https://pubmed.ncbi.nlm.nih.gov/28525305/
DLBCL|1.0|2022|Lenz, Georg|Hintergrund||Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017;35:2515-26|https://pubmed.ncbi.nlm.nih.gov/28525305/
DLBCL|1.0|2022|Ott, German|Hintergrund|LETZTAUTOR|Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017;35:2515-26|https://pubmed.ncbi.nlm.nih.gov/28525305/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017;35:2515-26|https://pubmed.ncbi.nlm.nih.gov/28525305/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund|LETZTAUTOR|Masqué-Soler N, Szczepanowski M, Kohler CW, Spang R, Klapper W. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood. 2013;122:1985-6|https://pubmed.ncbi.nlm.nih.gov/24030260/
DLBCL|1.0|2022|Ott, German|Hintergrund||Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214-7|https://pubmed.ncbi.nlm.nih.gov/24398326/
DLBCL|1.0|2022|Ott, German|Hintergrund||Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82|https://pubmed.ncbi.nlm.nih.gov/14504078/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund||Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, et al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2020;34:543-52|https://pubmed.ncbi.nlm.nih.gov/31530861/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, et al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2020;34:543-52|https://pubmed.ncbi.nlm.nih.gov/31530861/
DLBCL|1.0|2022|Ott, German|Hintergrund||Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, et al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2020;34:543-52|https://pubmed.ncbi.nlm.nih.gov/31530861/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, et al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2020;34:543-52|https://pubmed.ncbi.nlm.nih.gov/31530861/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia. 2015;29:1564-70|https://pubmed.ncbi.nlm.nih.gov/25687653/
DLBCL|1.0|2022|Ott, German|Hintergrund||Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia. 2015;29:1564-70|https://pubmed.ncbi.nlm.nih.gov/25687653/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia. 2015;29:1564-70|https://pubmed.ncbi.nlm.nih.gov/25687653/
DLBCL|1.0|2022|Klapper, Wolfram|Hintergrund||Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253-63|https://pubmed.ncbi.nlm.nih.gov/23335369/
DLBCL|1.0|2022|Ott, German|Hintergrund|LETZTAUTOR|Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253-63|https://pubmed.ncbi.nlm.nih.gov/23335369/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253-63|https://pubmed.ncbi.nlm.nih.gov/23335369/
DLBCL|1.0|2022|Ott, German|Hintergrund||Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396-407|https://pubmed.ncbi.nlm.nih.gov/29641966/
DLBCL|1.0|2022|Bewarder, Moritz|Empfehlung||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Bewarder, Moritz|Hintergrund||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Dührsen, Ulrich|Empfehlung||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Grosse, Jirka|Empfehlung||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Grosse, Jirka|Hintergrund||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Held, Gerhard|Empfehlung||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Hellwig, Dirk|Empfehlung|LETZTAUTOR|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Hellwig, Dirk|Hintergrund|LETZTAUTOR|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Hüttmann, Andreas|Empfehlung||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Kaddu-Mulindwa, Dominic|Empfehlung|ERSTAUTOR|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Kaddu-Mulindwa, Dominic|Hintergrund|ERSTAUTOR|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Thurner, Lorenz|Empfehlung||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Thurner, Lorenz|Hintergrund||Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund|ERSTAUTOR|Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112-8|https://pubmed.ncbi.nlm.nih.gov/24493716/
DLBCL|1.0|2022|Pöschel, Viola|Hintergrund||Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112-8|https://pubmed.ncbi.nlm.nih.gov/24493716/
DLBCL|1.0|2022|Rübe, Christian|Hintergrund||Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112-8|https://pubmed.ncbi.nlm.nih.gov/24493716/
DLBCL|1.0|2022|Dührsen, Ulrich|Empfehlung||Schmitz C, Hüttmann A, Müller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25-36|https://pubmed.ncbi.nlm.nih.gov/31710995/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund||Schmitz C, Hüttmann A, Müller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25-36|https://pubmed.ncbi.nlm.nih.gov/31710995/
DLBCL|1.0|2022|Hüttmann, Andreas|Empfehlung||Schmitz C, Hüttmann A, Müller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25-36|https://pubmed.ncbi.nlm.nih.gov/31710995/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund||Schmitz C, Hüttmann A, Müller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25-36|https://pubmed.ncbi.nlm.nih.gov/31710995/
DLBCL|1.0|2022|Kliesch, Sabine|Hintergrund|ERSTAUTOR|Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, et al. Management of germ cell tumours of the testes in adult patients: German clinical practice guideline, part II - Recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy. Urol Int. 2021;105:181-91|https://pubmed.ncbi.nlm.nih.gov/33486494/
DLBCL|1.0|2022|Schmidberger, Heinz|Hintergrund||Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, et al. Management of germ cell tumours of the testes in adult patients: German clinical practice guideline, part II - Recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy. Urol Int. 2021;105:181-91|https://pubmed.ncbi.nlm.nih.gov/33486494/
DLBCL|1.0|2022|Kliesch, Sabine|Hintergrund||Toth B, Baston-Büst DM, Behre HM, Bielfeld A, Bohlmann M, Bühling K, et al. Diagnosis and treatment before assisted reproductive treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 2, hemostaseology, andrology, genetics and history of malignant disease. Geburtshilfe Frauenheilkd. 2019;79:1293-308|https://pubmed.ncbi.nlm.nih.gov/31875859/
DLBCL|1.0|2022|Toth, Bettina|Hintergrund|ERSTAUTOR|Toth B, Baston-Büst DM, Behre HM, Bielfeld A, Bohlmann M, Bühling K, et al. Diagnosis and treatment before assisted reproductive treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 2, hemostaseology, andrology, genetics and history of malignant disease. Geburtshilfe Frauenheilkd. 2019;79:1293-308|https://pubmed.ncbi.nlm.nih.gov/31875859/
DLBCL|1.0|2022|Kliesch, Sabine|Hintergrund||Corona G, Minhas S, Giwercman A, Bettocchi C, Dinkelman-Smit M, Dohle G, et al. Sperm recovery and ICSI outcomes in men with non-obstructive azoospermia: a systematic review and meta-analysis. Hum Reprod Update. 2019;25:733-57|https://pubmed.ncbi.nlm.nih.gov/31665451/
DLBCL|1.0|2022|Berdel, Christian|Empfehlung||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Berdel, Christian|Hintergrund||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Borchmann, Peter|Empfehlung||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Borchmann, Peter|Hintergrund||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Held, Gerhard|Empfehlung||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Thurner, Lorenz|Empfehlung||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Thurner, Lorenz|Hintergrund||Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund||Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640-6|https://pubmed.ncbi.nlm.nih.gov/24297867/
DLBCL|1.0|2022|Held, Gerhard|Hintergrund||Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276-84|https://pubmed.ncbi.nlm.nih.gov/22337718/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund||Wagner B, Dührsen U, Hüttmann A, Nückel H, Michita RT, Rohn H, et al. Genetic variants of the NKG2C/HLA-E receptor-ligand axis are determinants of progression-free survival and therapy outcome in aggressive B-cell lymphoma. Cancers (Basel). 2020;12:|https://pubmed.ncbi.nlm.nih.gov/33218185/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund||Wagner B, Dührsen U, Hüttmann A, Nückel H, Michita RT, Rohn H, et al. Genetic variants of the NKG2C/HLA-E receptor-ligand axis are determinants of progression-free survival and therapy outcome in aggressive B-cell lymphoma. Cancers (Basel). 2020;12:|https://pubmed.ncbi.nlm.nih.gov/33218185/
DLBCL|1.0|2022|Dührsen, Ulrich|Hintergrund||Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:2605-16|https://pubmed.ncbi.nlm.nih.gov/33909455/
DLBCL|1.0|2022|Hüttmann, Andreas|Hintergrund||Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:2605-16|https://pubmed.ncbi.nlm.nih.gov/33909455/
DLBCL|1.0|2022|Kliesch, Sabine|Hintergrund||Dittrich R, Kliesch S, Schüring A, Balcerek M, Baston-Büst DM, Beck R, et al. Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM - Recommendations and statements for girls and women. Geburtshilfe Frauenheilkd. 2018;78:567-84|https://pubmed.ncbi.nlm.nih.gov/29962516/
DLBCL|1.0|2022|Micke, Oliver|Hintergrund||Dittrich R, Kliesch S, Schüring A, Balcerek M, Baston-Büst DM, Beck R, et al. Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM - Recommendations and statements for girls and women. Geburtshilfe Frauenheilkd. 2018;78:567-84|https://pubmed.ncbi.nlm.nih.gov/29962516/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-22|https://pubmed.ncbi.nlm.nih.gov/21940214/
DLBCL|1.0|2022|Liersch, Rüdiger|Empfehlung||Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16|https://pubmed.ncbi.nlm.nih.gov/18226581/
DLBCL|1.0|2022|Liersch, Rüdiger|Hintergrund||Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16|https://pubmed.ncbi.nlm.nih.gov/18226581/
DLBCL|1.0|2022|Trümper, Lorenz|Empfehlung||Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16|https://pubmed.ncbi.nlm.nih.gov/18226581/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16|https://pubmed.ncbi.nlm.nih.gov/18226581/
DLBCL|1.0|2022|Trümper, Lorenz|Empfehlung||Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-91|https://pubmed.ncbi.nlm.nih.gov/16648042/
DLBCL|1.0|2022|Trümper, Lorenz|Hintergrund||Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-91|https://pubmed.ncbi.nlm.nih.gov/16648042/
Malignes Melanom|3.3|2020|Garbe, Claus|Empfehlung|LETZTAUTOR|Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. . 2003;89:1620-1626|
Malignes Melanom|3.3|2020|Garbe, Claus|Hintergrund|LETZTAUTOR|Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. . 2003;4:748-759|
Malignes Melanom|3.3|2020|Garbe, Claus|Hintergrund|ERSTAUTOR|Garbe C, Eigentler TK. Treatment of malignant melanoma at the stage of distant metastasis. . 2004;55:195-212|
Adulte Weichgewebesarkome|1.1|2022|Bauer, Sebastian|Hintergrund|ERSTAUTOR|Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, et al. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous . Clin Cancer Res. 2021;27 (23):6333-6342|https://pubmed.ncbi.nlm.nih.gov/34503977/
Adulte Weichgewebesarkome|1.1|2022|Reichardt, Peter|Hintergrund||Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, et al. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous . Clin Cancer Res. 2021;27 (23):6333-6342|https://pubmed.ncbi.nlm.nih.gov/34503977/
Adulte Weichgewebesarkome|1.1|2022|Bauer, Sebastian|Empfehlung||Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21 (7):923-934|https://pubmed.ncbi.nlm.nih.gov/32511981/
Adulte Weichgewebesarkome|1.1|2022|Bauer, Sebastian|Hintergrund||Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21 (7):923-934|https://pubmed.ncbi.nlm.nih.gov/32511981/
Adulte Weichgewebesarkome|1.1|2022|Reichardt, Peter|Empfehlung||Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21 (7):923-934|https://pubmed.ncbi.nlm.nih.gov/32511981/
Adulte Weichgewebesarkome|1.1|2022|Reichardt, Peter|Hintergrund||Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21 (7):923-934|https://pubmed.ncbi.nlm.nih.gov/32511981/
Komplementärmedizin|1.1|2021|Micke, Oliver|Hintergrund||Huebner J, Muenstedt K, Muecke R, Micke O, Stoll C, Kleeberg UR, et al. Counseling cancer patients on complementary and alternative medicine. . 2013;189:613-617|https://pubmed.ncbi.nlm.nih.gov/23824107/
Chronisch lymphatische Leukämie (CLL)|1|2018|Eichhorst, Barbara|Empfehlung||Schweighofer C., Levy V., Müller C., Busch R., Porcher R., Ibach S., et al. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. None. 2013;122:Abstract 524|
Chronisch lymphatische Leukämie (CLL)|1|2018|Eichhorst, Barbara|Hintergrund||Schweighofer C., Levy V., Müller C., Busch R., Porcher R., Ibach S., et al. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. None. 2013;122:Abstract 524|
Chronisch lymphatische Leukämie (CLL)|1|2018|Stilgenbauer, Stephan|Empfehlung||Schweighofer C., Levy V., Müller C., Busch R., Porcher R., Ibach S., et al. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. None. 2013;122:Abstract 524|
Chronisch lymphatische Leukämie (CLL)|1|2018|Stilgenbauer, Stephan|Hintergrund||Schweighofer C., Levy V., Müller C., Busch R., Porcher R., Ibach S., et al. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. None. 2013;122:Abstract 524|
Chronisch lymphatische Leukämie (CLL)|1|2018|Bahlo, Jasmin|Hintergrund||Kovacs G, Böttcher S., Bahlo J, Kluth S, Ritgen M., Fink A-M, et al. Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). None. 2014;124:Abstract 23|
Chronisch lymphatische Leukämie (CLL)|1|2018|Eichhorst, Barbara|Hintergrund|LETZTAUTOR|Kovacs G, Böttcher S., Bahlo J, Kluth S, Ritgen M., Fink A-M, et al. Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). None. 2014;124:Abstract 23|
Chronisch lymphatische Leukämie (CLL)|1|2018|Eichhorst, Barbara|Hintergrund||Hallek M., Fischer K., Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia: a Randomised, Open-label, Phase III Trial. . 2010;376:1164-1174|
Chronisch lymphatische Leukämie (CLL)|1|2018|Stilgenbauer, Stephan|Hintergrund|LETZTAUTOR|Hallek M., Fischer K., Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia: a Randomised, Open-label, Phase III Trial. . 2010;376:1164-1174|
Chronisch lymphatische Leukämie (CLL)|1|2018|Eichhorst, Barbara|Hintergrund||Hallek M., Fischer K., Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia: a Randomised, Open-label, Phase III Trial. None. 2010;376:1164-1174|
Chronisch lymphatische Leukämie (CLL)|1|2018|Stilgenbauer, Stephan|Hintergrund|LETZTAUTOR|Hallek M., Fischer K., Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia: a Randomised, Open-label, Phase III Trial. None. 2010;376:1164-1174|
Mammakarzinom|4.4|2021|Loibl, Sibylle|Empfehlung|ERSTAUTOR|Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy–results from Paloma-3. None. 2016;34:abstr 524|
Mammakarzinom|4.4|2021|Loibl, Sibylle|Hintergrund|ERSTAUTOR|Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy–results from Paloma-3. None. 2016;34:abstr 524|
Mammakarzinom|4.4|2021|Weis, Joachim|Hintergrund|ERSTAUTOR|Weis J, Schumacher A, Blettner G, Determann M, Reinert E, Rüffer JU, et al. Psychoonkologie. None. 2007;13:185-194|
Mammakarzinom|4.4|2021|Weis, Joachim|Hintergrund||Poppelreuter M, Weis J, Schmid J, Bartsch HH. Neuropsychologische Folgestörungen nach adjuvanter Therapie des Mammakarzinoms. None. 2006;12:27-35|
Mammakarzinom|4.4|2021|Feyer, Petra|Hintergrund|LETZTAUTOR|Roila F, Herrstedt Jørn, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. None. 2010;21:v232-v243|
Mammakarzinom|4.4|2021|Link, Hartmut|Hintergrund|ERSTAUTOR|Link H, Buchheidt D, Maschmeyer G, Böhme A, Mahlberg R, Mousset S, et al. Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) dDGfHuOeVD, Sektion Infektionen in der Hämatologie und Onkologie dP-E-GfCeVP, Arbeitsgemeinschaft Supportivmaßnahmen in der Onkologie dDKeVA, Deutschsprachige Mykologische Gesellschaft eV (DMykG)(2006) Infektionen bei Neutropenie–Diagnostik und Therapie 2006–Empfehlungen für die Praxis. None. 2006;None:None|
Mammakarzinom|4.4|2021|Schneeweiss, Andreas|Hintergrund||Hahnen E., Lederer B., Hauke J., Loibl S., Kröber S., Schneeweiss A, et al. Germline mutation status, pathological complete response and disease-free survival rates in triple-negative breast cancer (GeparSixto trial), A Randomized Clinical Trial. None. 2017;None:None|
Mammakarzinom|4.4|2021|Rick, Oliver|Hintergrund|ERSTAUTOR|Rick O, Mikus E, Dertinger H, Geiger G. Treatment of chemotherapy-induced polyneuropathy with magnetic field therapy: A randomized, double-blind placebo-controlled comparative phase Iii study. None. 2014;37:189|
Mammakarzinom|4.4|2021|Müller-Schimpfle, Markus|Empfehlung|ERSTAUTOR|Müller-Schimpfle M, Graf O, Madjar H, al. et. Diskussionspapier - BI-RADS die 5. - eine Kurzmitteilung aus deutsch- /österreichischer Sicht. None. 2016;None:346-352|
Mammakarzinom|4.4|2021|Schneeweiss, Andreas|Hintergrund|ERSTAUTOR|Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). None. 2013;24:2278-2284|
Hautkrebsprävention|2.1|2021|Matzarakis, Andreas|Hintergrund|LETZTAUTOR|Muthers S, aschewski G, Matzarakis A. The Summers 2003 and 2015 in South-West Germany: HeatWaves and Heat-Related Mortality in the Context of Climate Change. None. 2017;8:224|
Hautkrebsprävention|2.1|2021|Baumann, Eva|Hintergrund|ERSTAUTOR|Baumann E. Auf der Suche nach der Zielgruppe - Das Informationsverhalten hinsichtlich Gesundheit und Krankheit als Grundlage erfolgreicher Gesundheitskommunikation. None. 2006;None:117-153|
Nierenzellkarzinom|3.0|2021|Bex, Axel|Empfehlung||Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, et al. Guidelines on renal cell carcinoma. None. 2013;None:None|
Nierenzellkarzinom|3.0|2021|Bex, Axel|Hintergrund||Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, et al. Guidelines on renal cell carcinoma. None. 2013;None:None|
Nierenzellkarzinom|3.0|2021|Staehler, Michael|Empfehlung||Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, et al. Guidelines on renal cell carcinoma. None. 2013;None:None|
Nierenzellkarzinom|3.0|2021|Staehler, Michael|Hintergrund||Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, et al. Guidelines on renal cell carcinoma. None. 2013;None:None|
Endometriumkarzinom|2.0|2022|Weis, Joachim|Hintergrund||Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013;31 (6):782-93|https://pubmed.ncbi.nlm.nih.gov/23319686/
Endometriumkarzinom|2.0|2022|Kommoss, Stefan|Hintergrund||van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020;30 (12):2002-2007|https://pubmed.ncbi.nlm.nih.gov/33046573/
Endometriumkarzinom|2.0|2022|Kommoss, Stefan|Empfehlung|ERSTAUTOR|Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29 (5):1180-1188|https://pubmed.ncbi.nlm.nih.gov/29432521/
Endometriumkarzinom|2.0|2022|Kommoss, Stefan|Hintergrund|ERSTAUTOR|Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29 (5):1180-1188|https://pubmed.ncbi.nlm.nih.gov/29432521/
Endometriumkarzinom|2.0|2022|Lax, Sigurd|Empfehlung||Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29 (5):1180-1188|https://pubmed.ncbi.nlm.nih.gov/29432521/
Endometriumkarzinom|2.0|2022|Lax, Sigurd|Hintergrund||Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29 (5):1180-1188|https://pubmed.ncbi.nlm.nih.gov/29432521/
Endometriumkarzinom|2.0|2022|Kommoss, Stefan|Hintergrund|LETZTAUTOR|Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018;119 (4):480-486|https://pubmed.ncbi.nlm.nih.gov/30050154/
Endometriumkarzinom|2.0|2022|Tempfer, Clemens|Empfehlung||Dörk T, Hillemanns P, Tempfer C, Breu J, Fleisch MC. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32854222/
Endometriumkarzinom|2.0|2022|Tempfer, Clemens|Hintergrund||Dörk T, Hillemanns P, Tempfer C, Breu J, Fleisch MC. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32854222/
Endometriumkarzinom|2.0|2022|Emons, Günter|Empfehlung|ERSTAUTOR|Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32906618/
Endometriumkarzinom|2.0|2022|Mustea, Alexander|Empfehlung||Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32906618/
Endometriumkarzinom|2.0|2022|Tempfer, Clemens|Empfehlung|LETZTAUTOR|Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32906618/
Endometriumkarzinom|2.0|2022|Ortmann, Olaf|Empfehlung|LETZTAUTOR|Ignatov A, Ortmann O. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers (Basel). 2020;12 (7):|https://pubmed.ncbi.nlm.nih.gov/32630728/
Endometriumkarzinom|2.0|2022|Ortmann, Olaf|Hintergrund|LETZTAUTOR|Ignatov A, Ortmann O. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers (Basel). 2020;12 (7):|https://pubmed.ncbi.nlm.nih.gov/32630728/
Endometriumkarzinom|2.0|2022|Vordermark, Dirk|Hintergrund|ERSTAUTOR|Vordermark D, Medenwald D, Izaguirre V, Sieker F, Marnitz S. The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus. Cancers (Basel). 2020;12 (12):|https://pubmed.ncbi.nlm.nih.gov/33265910/
Endometriumkarzinom|2.0|2022|Lax, Sigurd|Hintergrund||Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31 (1):12-39|https://pubmed.ncbi.nlm.nih.gov/33397713/
Endometriumkarzinom|2.0|2022|Emons, Günter|Hintergrund|ERSTAUTOR|Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75 (2):135-136|https://pubmed.ncbi.nlm.nih.gov/25797956/
Endometriumkarzinom|2.0|2022|Mallmann, Peter|Hintergrund|LETZTAUTOR|Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75 (2):135-136|https://pubmed.ncbi.nlm.nih.gov/25797956/
Endometriumkarzinom|2.0|2022|Mayr, Doris|Hintergrund||Höhn AK, Brambs CE, Erber R, Hiller GGR, Mayr D, Schmidt D, et al. [Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes]. Pathologe. 2021;42 (3):319-327|https://pubmed.ncbi.nlm.nih.gov/32700061/
Endometriumkarzinom|2.0|2022|Lax, Sigurd|Hintergrund||Cho KR, Cooper K, Croce S, Djordevic B, Herrington S, Howitt B, et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019;38 Suppl 1 ():S114-S122|https://pubmed.ncbi.nlm.nih.gov/29521846/
Endometriumkarzinom|2.0|2022|Kommoss, Stefan|Empfehlung||Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019;154 (1):124-130|https://pubmed.ncbi.nlm.nih.gov/31103324/
Endometriumkarzinom|2.0|2022|Kommoss, Stefan|Hintergrund||Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019;154 (1):124-130|https://pubmed.ncbi.nlm.nih.gov/31103324/
Endometriumkarzinom|2.0|2022|Kommoss, Stefan|Hintergrund||Marnitz S, Walter T, Schömig-Markiefka B, Engler T, Kommoss S, Brucker SY. A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32927671/
Endometriumkarzinom|2.0|2022|Mallmann, Peter|Hintergrund||Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, et al. [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology]. Pathologe. 2015;36 (6):585-93|https://pubmed.ncbi.nlm.nih.gov/26483249/
Endometriumkarzinom|2.0|2022|Ortmann, Olaf|Hintergrund||Ignatov A, Lebius C, Ignatov T, Ivros S, Knueppel R, Papathemelis T, et al. Lymph node micrometastases and outcome of endometrial cancer. Gynecol Oncol. 2019;154 (3):475-479|https://pubmed.ncbi.nlm.nih.gov/31345606/
Endometriumkarzinom|2.0|2022|Weis, Joachim|Hintergrund||Fabi A, Bhargava R, Fatigoni S, Guglielmo M, Horneber M, Roila F, et al. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment. Ann Oncol. 2020;31 (6):713-723|https://pubmed.ncbi.nlm.nih.gov/32173483/
Ösophaguskarzinom|3.1|2022|Fischbach, Wolfgang|Empfehlung||Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393 (10184):1948-1957|https://pubmed.ncbi.nlm.nih.gov/30982686/
Ösophaguskarzinom|3.1|2022|Mönig, Stefan|Empfehlung||Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393 (10184):1948-1957|https://pubmed.ncbi.nlm.nih.gov/30982686/
Ösophaguskarzinom|3.1|2022|Thuss-Patience, Peter|Empfehlung||Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393 (10184):1948-1957|https://pubmed.ncbi.nlm.nih.gov/30982686/
Ösophaguskarzinom|3.1|2022|Trojan, Jörg|Empfehlung||Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393 (10184):1948-1957|https://pubmed.ncbi.nlm.nih.gov/30982686/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|LETZTAUTOR|Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021;85 (6):1510-1519|https://pubmed.ncbi.nlm.nih.gov/33744350/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Drexler, Hans|Hintergrund||Voelter-Mahlknecht S, Scheriau R, Zwahr G, Koch B, Escobar Pinzon LC, Drexler H, et al. Skin tumors among employees of a tar refinery: the current data and their implications. Int Arch Occup Environ Health. 2007;80 (6):485-95|https://pubmed.ncbi.nlm.nih.gov/17093963/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Hauschild, Axel|Empfehlung|ERSTAUTOR|Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Hauschild, Axel|Hintergrund|ERSTAUTOR|Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Empfehlung||Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Hintergrund||Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Empfehlung|LETZTAUTOR|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|LETZTAUTOR|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Empfehlung|ERSTAUTOR|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund|ERSTAUTOR|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Empfehlung||Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Hintergrund||Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|LETZTAUTOR|Schmitz L, Gambichler T, Gupta G, Stücker M, Stockfleth E, Szeimies RM, et al. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32 (5):745-751|https://pubmed.ncbi.nlm.nih.gov/28796914/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund|ERSTAUTOR|Schmitz L, Gambichler T, Gupta G, Stücker M, Stockfleth E, Szeimies RM, et al. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32 (5):745-751|https://pubmed.ncbi.nlm.nih.gov/28796914/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Hintergrund||Schmitz L, Gambichler T, Gupta G, Stücker M, Stockfleth E, Szeimies RM, et al. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32 (5):745-751|https://pubmed.ncbi.nlm.nih.gov/28796914/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|LETZTAUTOR|Schmitz L, Gambichler T, Kost C, Gupta G, Stücker M, Stockfleth E, et al. Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses. Br J Dermatol. 2019;180 (4):916-921|https://pubmed.ncbi.nlm.nih.gov/29526028/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund|ERSTAUTOR|Schmitz L, Gambichler T, Kost C, Gupta G, Stücker M, Stockfleth E, et al. Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses. Br J Dermatol. 2019;180 (4):916-921|https://pubmed.ncbi.nlm.nih.gov/29526028/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Hintergrund||Schmitz L, Gambichler T, Kost C, Gupta G, Stücker M, Stockfleth E, et al. Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses. Br J Dermatol. 2019;180 (4):916-921|https://pubmed.ncbi.nlm.nih.gov/29526028/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Empfehlung|ERSTAUTOR|Dirschka T, Pellacani G, Micali G, Malvehy J, Stratigos AJ, Casari A, et al. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31 (8):1295-1302|https://pubmed.ncbi.nlm.nih.gov/28401585/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|ERSTAUTOR|Dirschka T, Pellacani G, Micali G, Malvehy J, Stratigos AJ, Casari A, et al. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31 (8):1295-1302|https://pubmed.ncbi.nlm.nih.gov/28401585/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Empfehlung||Dirschka T, Pellacani G, Micali G, Malvehy J, Stratigos AJ, Casari A, et al. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31 (8):1295-1302|https://pubmed.ncbi.nlm.nih.gov/28401585/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund||Dirschka T, Pellacani G, Micali G, Malvehy J, Stratigos AJ, Casari A, et al. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31 (8):1295-1302|https://pubmed.ncbi.nlm.nih.gov/28401585/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Garbe, Claus|Hintergrund||Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128 ():83-102|https://pubmed.ncbi.nlm.nih.gov/32113942/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Hauschild, Axel|Hintergrund||Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128 ():83-102|https://pubmed.ncbi.nlm.nih.gov/32113942/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Gutzmer, Ralf|Hintergrund||Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138 ():125-132|https://pubmed.ncbi.nlm.nih.gov/32882466/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund||Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138 ():125-132|https://pubmed.ncbi.nlm.nih.gov/32882466/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Loquai, Carmen|Hintergrund||Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138 ():125-132|https://pubmed.ncbi.nlm.nih.gov/32882466/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Becker, Jürgen|Hintergrund||Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Gutzmer, Ralf|Hintergrund||Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Hauschild, Axel|Hintergrund||Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Hillen, Uwe|Hintergrund|ERSTAUTOR|Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Krause-Bergmann, Albrecht|Hintergrund||Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund||Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Mohr, Peter|Hintergrund||Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Garbe, Claus|Hintergrund||Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018;104 ():137-144|https://pubmed.ncbi.nlm.nih.gov/30347289/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Gutzmer, Ralf|Hintergrund||Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018;104 ():137-144|https://pubmed.ncbi.nlm.nih.gov/30347289/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Gutzmer, Ralf|Hintergrund|LETZTAUTOR|Kähler KC, Egberts F, Gutzmer R. Palliative treatment of skin metastases in dermato-oncology. J Dtsch Dermatol Ges. 2013;11 (11):1041-5; quiz 1046|https://pubmed.ncbi.nlm.nih.gov/24015966/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Empfehlung|LETZTAUTOR|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|LETZTAUTOR|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Empfehlung|ERSTAUTOR|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund|ERSTAUTOR|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Empfehlung||Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Hintergrund||Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Welzel, Julia|Empfehlung||Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Welzel, Julia|Hintergrund||Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund|ERSTAUTOR|Breuninger H, Eigentler T, Häfner HM, Leiter U. None. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31631533/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Eigentler, Thomas|Hintergrund||Breuninger H, Eigentler T, Häfner HM, Leiter U. None. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31631533/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund|LETZTAUTOR|Breuninger H, Eigentler T, Häfner HM, Leiter U. None. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31631533/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund|ERSTAUTOR|Breuninger H, Eigentler T, Häfner HM, Leiter U. Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31545559/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Eigentler, Thomas|Hintergrund||Breuninger H, Eigentler T, Häfner HM, Leiter U. Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31545559/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund|LETZTAUTOR|Breuninger H, Eigentler T, Häfner HM, Leiter U. Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31545559/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Garbe, Claus|Hintergrund||Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128 ():60-82|https://pubmed.ncbi.nlm.nih.gov/32113941/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Hauschild, Axel|Hintergrund||Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128 ():60-82|https://pubmed.ncbi.nlm.nih.gov/32113941/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund||Haug K, Breuninger H, Metzler G, Eigentler T, Eichner M, Häfner HM, et al. Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors. J Invest Dermatol. 2020;140 (10):1968-1975|https://pubmed.ncbi.nlm.nih.gov/32169476/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Eigentler, Thomas|Hintergrund||Haug K, Breuninger H, Metzler G, Eigentler T, Eichner M, Häfner HM, et al. Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors. J Invest Dermatol. 2020;140 (10):1968-1975|https://pubmed.ncbi.nlm.nih.gov/32169476/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund||Kofler L, Kofler K, Schulz C, Breuninger H, Häfner HM. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma. Arch Dermatol Res. 2021;313 (2):119-126|https://pubmed.ncbi.nlm.nih.gov/32385689/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Kofler, Lukas|Hintergrund|ERSTAUTOR|Kofler L, Kofler K, Schulz C, Breuninger H, Häfner HM. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma. Arch Dermatol Res. 2021;313 (2):119-126|https://pubmed.ncbi.nlm.nih.gov/32385689/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund|LETZTAUTOR|Hoetzenecker W, Guenova E, Böttinger TU, Häfner HM, Breuninger H. Mapping of specific sentinel node locations for skin cancer of the head. Eur J Dermatol. ;21 (3):354-8|https://pubmed.ncbi.nlm.nih.gov/21680279/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Empfehlung|ERSTAUTOR|Berking C, Herzinger T, Flaig MJ, Brenner M, Borelli C, Degitz K. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg. 2007;33 (7):825-30|https://pubmed.ncbi.nlm.nih.gov/17598848/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Hintergrund|ERSTAUTOR|Berking C, Herzinger T, Flaig MJ, Brenner M, Borelli C, Degitz K. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg. 2007;33 (7):825-30|https://pubmed.ncbi.nlm.nih.gov/17598848/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund|LETZTAUTOR|Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137 (11):2309-2315|https://pubmed.ncbi.nlm.nih.gov/28736229/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Garbe, Claus|Hintergrund||Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137 (11):2309-2315|https://pubmed.ncbi.nlm.nih.gov/28736229/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund||Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137 (11):2309-2315|https://pubmed.ncbi.nlm.nih.gov/28736229/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund|LETZTAUTOR|Eberle FC, Kanyildiz M, Schnabl SM, Schulz C, Häfner HM, Adam P, et al. Three dimensional (3D) histology in daily routine: practical implementation and its evaluation. J Dtsch Dermatol Ges. 2014;12 (11):1028-35|https://pubmed.ncbi.nlm.nih.gov/25354011/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund|LETZTAUTOR|Boehringer A, Adam P, Schnabl S, Häfner HM, Breuninger H. Analysis of incomplete excisions of basal-cell carcinomas after breadloaf microscopy compared with 3D-microscopy: a prospective randomized and blinded study. J Cutan Pathol. 2015;42 (8):542-53|https://pubmed.ncbi.nlm.nih.gov/25975523/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund||Kofler L, Breuninger H, Schreiber RH, Eichner M, Häfner HM, Schnabl SM. Three-dimensional histology vs. serial section histology in the treatment of primary basal cell carcinoma: a randomized, prospective, blinded study of 569 tumours. J Eur Acad Dermatol Venereol. 2021;35 (6):1323-1330|https://pubmed.ncbi.nlm.nih.gov/33539573/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Kofler, Lukas|Hintergrund|ERSTAUTOR|Kofler L, Breuninger H, Schreiber RH, Eichner M, Häfner HM, Schnabl SM. Three-dimensional histology vs. serial section histology in the treatment of primary basal cell carcinoma: a randomized, prospective, blinded study of 569 tumours. J Eur Acad Dermatol Venereol. 2021;35 (6):1323-1330|https://pubmed.ncbi.nlm.nih.gov/33539573/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund|LETZTAUTOR|Löser CR, Rompel R, Möhrle M, Häfner HM, Kunte C, Hassel J, et al. S1 guideline: microscopically controlled surgery (MCS). J Dtsch Dermatol Ges. 2015;13 (9):942-51|https://pubmed.ncbi.nlm.nih.gov/26882393/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Breuninger, Helmut|Hintergrund||Kofler L, Breuninger H, Schulz C, Häfner HM, Kofler K. Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities. Dermatol Surg. 2021;47 (2):e31-e36|https://pubmed.ncbi.nlm.nih.gov/33565775/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Kofler, Lukas|Hintergrund|ERSTAUTOR|Kofler L, Breuninger H, Schulz C, Häfner HM, Kofler K. Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities. Dermatol Surg. 2021;47 (2):e31-e36|https://pubmed.ncbi.nlm.nih.gov/33565775/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Empfehlung|LETZTAUTOR|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|LETZTAUTOR|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Empfehlung|ERSTAUTOR|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund|ERSTAUTOR|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Empfehlung||Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Hintergrund||Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Empfehlung||Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Hintergrund||Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Empfehlung||Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund||Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Empfehlung|ERSTAUTOR|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Hintergrund|ERSTAUTOR|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Empfehlung|LETZTAUTOR|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Hintergrund|LETZTAUTOR|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Empfehlung||Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Hintergrund||Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Empfehlung|LETZTAUTOR|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Hintergrund|LETZTAUTOR|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Empfehlung||Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund||Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Empfehlung||Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Hintergrund||Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Empfehlung||Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Hintergrund||Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Empfehlung||Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Schmitz, Lutz|Hintergrund||Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Empfehlung|ERSTAUTOR|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Hintergrund|ERSTAUTOR|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Empfehlung|LETZTAUTOR|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Hintergrund|LETZTAUTOR|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Empfehlung|ERSTAUTOR|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Hintergrund|ERSTAUTOR|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Empfehlung||Gollnick H, Dirschka T, Ostendorf R, Kerl H, Kunstfeld R. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2020;34 (1):82-89|https://pubmed.ncbi.nlm.nih.gov/31407414/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund||Gollnick H, Dirschka T, Ostendorf R, Kerl H, Kunstfeld R. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2020;34 (1):82-89|https://pubmed.ncbi.nlm.nih.gov/31407414/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Empfehlung|ERSTAUTOR|Stockfleth E, Harwood CA, Serra-Guillén C, Larsson T, Østerdal ML, Skov T. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Br J Dermatol. 2018;178 (2):433-442|https://pubmed.ncbi.nlm.nih.gov/29030864/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Stockfleth, Eggert|Hintergrund|ERSTAUTOR|Stockfleth E, Harwood CA, Serra-Guillén C, Larsson T, Østerdal ML, Skov T. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Br J Dermatol. 2018;178 (2):433-442|https://pubmed.ncbi.nlm.nih.gov/29030864/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|LETZTAUTOR|Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021; ():|https://pubmed.ncbi.nlm.nih.gov/33744350/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Empfehlung|ERSTAUTOR|Dirschka T, Ekanayake-Bohlig S, Dominicus R, Aschoff R, Herrera-Ceballos E, Botella-Estrada R, et al. A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J Eur Acad Dermatol Venereol. 2019;33 (2):288-297|https://pubmed.ncbi.nlm.nih.gov/30022544/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Dirschka, Thomas|Hintergrund|ERSTAUTOR|Dirschka T, Ekanayake-Bohlig S, Dominicus R, Aschoff R, Herrera-Ceballos E, Botella-Estrada R, et al. A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J Eur Acad Dermatol Venereol. 2019;33 (2):288-297|https://pubmed.ncbi.nlm.nih.gov/30022544/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Empfehlung|LETZTAUTOR|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Berking, Carola|Hintergrund|LETZTAUTOR|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Garbe, Claus|Empfehlung||Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Garbe, Claus|Hintergrund||Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Empfehlung||Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund||Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Empfehlung||Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Steeb, Theresa|Hintergrund||Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Garbe, Claus|Hintergrund||Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U. Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol. 2019;33 Suppl 8 ():44-51|https://pubmed.ncbi.nlm.nih.gov/31658392/
Aktinische Keratose und Plattenepithelkarzinom der Haut|2.0|2022|Leiter, Ulrike|Hintergrund|LETZTAUTOR|Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U. Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol. 2019;33 Suppl 8 ():44-51|https://pubmed.ncbi.nlm.nih.gov/31658392/
Hodgkin Lymphom|3.2|2022|Engert, Andreas|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019;9 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31525824/
Hodgkin Lymphom|3.2|2022|Kobe, Carsten|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019;9 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31525824/
Hodgkin Lymphom|3.2|2022|Kreuzberger, Nina|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019;9 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31525824/
Hodgkin Lymphom|3.2|2022|Skoetz, Nicole|Hintergrund|LETZTAUTOR|Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019;9 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31525824/
Hodgkin Lymphom|3.2|2022|von Tresckow, Bastian|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019;9 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31525824/
Hodgkin Lymphom|3.2|2022|Engert, Andreas|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2020;1 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31930780/
Hodgkin Lymphom|3.2|2022|Kobe, Carsten|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2020;1 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31930780/
Hodgkin Lymphom|3.2|2022|Kreuzberger, Nina|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2020;1 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31930780/
Hodgkin Lymphom|3.2|2022|Skoetz, Nicole|Hintergrund|LETZTAUTOR|Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2020;1 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31930780/
Hodgkin Lymphom|3.2|2022|von Tresckow, Bastian|Hintergrund||Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2020;1 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31930780/
Hodgkin Lymphom|3.2|2022|Hentrich, Marcus|Hintergrund||Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2015;16 (4):261-4|https://pubmed.ncbi.nlm.nih.gov/25252101/
Hodgkin Lymphom|3.2|2022|Wyen, Christoph|Hintergrund|LETZTAUTOR|Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2015;16 (4):261-4|https://pubmed.ncbi.nlm.nih.gov/25252101/
Hodgkin Lymphom|3.2|2022|Hentrich, Marcus|Hintergrund|LETZTAUTOR|Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, et al. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS. 2016;30 (5):753-60|https://pubmed.ncbi.nlm.nih.gov/26605513/
Hodgkin Lymphom|3.2|2022|Wyen, Christoph|Hintergrund||Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, et al. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS. 2016;30 (5):753-60|https://pubmed.ncbi.nlm.nih.gov/26605513/
Hodgkin Lymphom|3.2|2022|Borchmann, Peter|Hintergrund||Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/
Hodgkin Lymphom|3.2|2022|Böll, Boris|Hintergrund||Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/
Hodgkin Lymphom|3.2|2022|Engert, Andreas|Hintergrund|LETZTAUTOR|Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/
Hodgkin Lymphom|3.2|2022|Fuchs, Michael|Hintergrund||Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/
Hodgkin Lymphom|3.2|2022|von Tresckow, Bastian|Hintergrund||Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/
Hodgkin Lymphom|3.2|2022|Engert, Andreas|Hintergrund||Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, et al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. Br J Haematol. 2018;183 (3):400-410|https://pubmed.ncbi.nlm.nih.gov/30168134/
Hodgkin Lymphom|3.2|2022|von Tresckow, Bastian|Hintergrund|LETZTAUTOR|Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, et al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. Br J Haematol. 2018;183 (3):400-410|https://pubmed.ncbi.nlm.nih.gov/30168134/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Trojan, Jörg|Hintergrund||Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49 (10):1323-1333|https://pubmed.ncbi.nlm.nih.gov/30980420/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Vogel, Arndt|Hintergrund||Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49 (10):1323-1333|https://pubmed.ncbi.nlm.nih.gov/30980420/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Waidmann, Oliver|Hintergrund||Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49 (10):1323-1333|https://pubmed.ncbi.nlm.nih.gov/30980420/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Wege, Henning|Hintergrund||Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49 (10):1323-1333|https://pubmed.ncbi.nlm.nih.gov/30980420/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Bitzer, Michael|Hintergrund|LETZTAUTOR|Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, et al. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers (Basel). 2020;12 (12):|https://pubmed.ncbi.nlm.nih.gov/33353145/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Vogel, Arndt|Empfehlung|LETZTAUTOR|Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21 (5):671-684|https://pubmed.ncbi.nlm.nih.gov/32203698/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Bitzer, Michael|Hintergrund||Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6 (10):803-815|https://pubmed.ncbi.nlm.nih.gov/34358484/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Geier, Andreas|Hintergrund||Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020;18 (3):728-735.e4|https://pubmed.ncbi.nlm.nih.gov/31712073/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Vogel, Arndt|Hintergrund||Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020;18 (3):728-735.e4|https://pubmed.ncbi.nlm.nih.gov/31712073/
Hepatozelluläres Karzinom und biliäre Karzinome|3.0|2022|Wege, Henning|Hintergrund||Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020;18 (3):728-735.e4|https://pubmed.ncbi.nlm.nih.gov/31712073/
Palliativmedizin|2.2|2020|Frohnhofen, Helmut|Hintergrund|ERSTAUTOR|Frohnhofen H, Bibl M, Nickel B, Popp R. Der Essener Fragebogen Alter und Schläfrigkeit ( EFAS ) – ein neues Assessmentinstrument zur Messung von Tagesschläfrigkeit bei alten. None. 2010;12:84-90|
Palliativmedizin|2.2|2020|Nieland, Peter|Hintergrund||Mehne S, Nieland P, Simander R. Basiscurriculum Physiotherapie in Palliative Care Palliativmedizin und Hospizwesen. . 2007;:|
Palliativmedizin|2.2|2020|Roser, Traugott|Hintergrund||Hagen T., Roser T, Reigber H., Fittgau-T&#246;nnesmann B. Qualifizierungskurs Palliative Care f&#252;r Seelsorgende. . 2010;:74|
Palliativmedizin|2.2|2020|Lipp, Volker|Hintergrund|ERSTAUTOR|Lipp V. Die medizinische Indikation – ein „Kernstück ärztlicher Legitimation“?. None. 2015;33:762-766|
Zervixkarzinom|2.2|2022|Wittekind, Christian|Hintergrund|ERSTAUTOR|Wittekind C. TNM Klassifikation maligner Tumoren - Korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019. None. 2020;None:None|
Zervixkarzinom|2.2|2022|Wittekind, Christian|Hintergrund|ERSTAUTOR|Wittekind C, Meyer HJ. TNM-Klassifikation maligner Tumoren. None. 2010;None:None|
Zervixkarzinom|2.2|2022|Wittekind, Christian|Hintergrund|ERSTAUTOR|Wittekind C, Compton CC, Brirley J, Sobin LH. TNM Supplement. A Comentary on Uniform USe. None. 2012;None:None|
Lungenkarzinom|2.1|2022|Griesinger, Frank|Empfehlung||Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021;16 (12):2091-2108|https://pubmed.ncbi.nlm.nih.gov/34537440/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund||Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021;16 (12):2091-2108|https://pubmed.ncbi.nlm.nih.gov/34537440/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Empfehlung||Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020;38 (31):3592-3603|https://pubmed.ncbi.nlm.nih.gov/32780660/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund||Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020;38 (31):3592-3603|https://pubmed.ncbi.nlm.nih.gov/32780660/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Empfehlung||Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379 (21):2027-2039|https://pubmed.ncbi.nlm.nih.gov/30280657/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund||Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379 (21):2027-2039|https://pubmed.ncbi.nlm.nih.gov/30280657/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund||Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, et al. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022;28 (6):1117-1126|https://pubmed.ncbi.nlm.nih.gov/34789481/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, et al. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022;28 (6):1117-1126|https://pubmed.ncbi.nlm.nih.gov/34789481/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Empfehlung|ERSTAUTOR|Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund|ERSTAUTOR|Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/
Lungenkarzinom|2.1|2022|Thomas, Michael|Empfehlung||Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/
Lungenkarzinom|2.1|2022|Thomas, Michael|Empfehlung||Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22 (7):959-969|https://pubmed.ncbi.nlm.nih.gov/34118197/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22 (7):959-969|https://pubmed.ncbi.nlm.nih.gov/34118197/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G, Reck M, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135 ():188-195|https://pubmed.ncbi.nlm.nih.gov/31446994/
Lungenkarzinom|2.1|2022|Junker, Klaus|Hintergrund||Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9 (7):636-48|https://pubmed.ncbi.nlm.nih.gov/18583190/
Lungenkarzinom|2.1|2022|Rübe, Christian|Hintergrund||Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9 (7):636-48|https://pubmed.ncbi.nlm.nih.gov/18583190/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund|ERSTAUTOR|Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9 (7):636-48|https://pubmed.ncbi.nlm.nih.gov/18583190/
Lungenkarzinom|2.1|2022|Junker, Klaus|Empfehlung|ERSTAUTOR|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/
Lungenkarzinom|2.1|2022|Junker, Klaus|Hintergrund|ERSTAUTOR|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/
Lungenkarzinom|2.1|2022|Thomas, Michael|Empfehlung|LETZTAUTOR|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund|LETZTAUTOR|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung|LETZTAUTOR|Eberhardt WE, Stamatis G, Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet. 2009;374 (9687):359-60|https://pubmed.ncbi.nlm.nih.gov/19632715/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund|LETZTAUTOR|Eberhardt WE, Stamatis G, Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet. 2009;374 (9687):359-60|https://pubmed.ncbi.nlm.nih.gov/19632715/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Empfehlung||Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol. 2002;13 (3):403-11|https://pubmed.ncbi.nlm.nih.gov/11996471/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Hintergrund||Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol. 2002;13 (3):403-11|https://pubmed.ncbi.nlm.nih.gov/11996471/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung|LETZTAUTOR|Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol. 2002;13 (3):403-11|https://pubmed.ncbi.nlm.nih.gov/11996471/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund|LETZTAUTOR|Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol. 2002;13 (3):403-11|https://pubmed.ncbi.nlm.nih.gov/11996471/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Empfehlung||Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, et al. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol. 2019;14 (1):115-123|https://pubmed.ncbi.nlm.nih.gov/30267838/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund||Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, et al. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol. 2019;14 (1):115-123|https://pubmed.ncbi.nlm.nih.gov/30267838/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Empfehlung||Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, et al. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34 (21):2526-33|https://pubmed.ncbi.nlm.nih.gov/27247220/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Hintergrund||Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, et al. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34 (21):2526-33|https://pubmed.ncbi.nlm.nih.gov/27247220/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung|LETZTAUTOR|Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, et al. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34 (21):2526-33|https://pubmed.ncbi.nlm.nih.gov/27247220/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund|LETZTAUTOR|Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, et al. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34 (21):2526-33|https://pubmed.ncbi.nlm.nih.gov/27247220/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Empfehlung||Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Hintergrund||Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung|LETZTAUTOR|Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund|LETZTAUTOR|Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/
Lungenkarzinom|2.1|2022|Hoffmann, Hans|Hintergrund||Rieber J, Deeg A, Ullrich E, Foerster R, Bischof M, Warth A, et al. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC). Lung Cancer. 2016;91 ():41-7|https://pubmed.ncbi.nlm.nih.gov/26711933/
Lungenkarzinom|2.1|2022|Rieken, Stefan|Hintergrund|LETZTAUTOR|Rieber J, Deeg A, Ullrich E, Foerster R, Bischof M, Warth A, et al. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC). Lung Cancer. 2016;91 ():41-7|https://pubmed.ncbi.nlm.nih.gov/26711933/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Rieber J, Deeg A, Ullrich E, Foerster R, Bischof M, Warth A, et al. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC). Lung Cancer. 2016;91 ():41-7|https://pubmed.ncbi.nlm.nih.gov/26711933/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung||Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, et al. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve. Eur J Cancer. 2020;138 ():156-168|https://pubmed.ncbi.nlm.nih.gov/32889370/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund||Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, et al. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve. Eur J Cancer. 2020;138 ():156-168|https://pubmed.ncbi.nlm.nih.gov/32889370/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung||Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16 (5):860-867|https://pubmed.ncbi.nlm.nih.gov/33476803/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16 (5):860-867|https://pubmed.ncbi.nlm.nih.gov/33476803/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Empfehlung|LETZTAUTOR|Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, et al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer. 2015;15 ():363|https://pubmed.ncbi.nlm.nih.gov/25943191/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Hintergrund|LETZTAUTOR|Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, et al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer. 2015;15 ():363|https://pubmed.ncbi.nlm.nih.gov/25943191/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung||Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, et al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer. 2015;15 ():363|https://pubmed.ncbi.nlm.nih.gov/25943191/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund||Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, et al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer. 2015;15 ():363|https://pubmed.ncbi.nlm.nih.gov/25943191/
Lungenkarzinom|2.1|2022|Dickgreber, Nikolas|Empfehlung||Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/
Lungenkarzinom|2.1|2022|Dickgreber, Nikolas|Hintergrund||Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/
Lungenkarzinom|2.1|2022|Flentje, Michael|Empfehlung|ERSTAUTOR|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/
Lungenkarzinom|2.1|2022|Flentje, Michael|Hintergrund|ERSTAUTOR|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/
Lungenkarzinom|2.1|2022|Kollmeier, Jens|Empfehlung||Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/
Lungenkarzinom|2.1|2022|Kollmeier, Jens|Hintergrund||Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/
Lungenkarzinom|2.1|2022|Fleckenstein, Jochen|Empfehlung||Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21 (4):581-592|https://pubmed.ncbi.nlm.nih.gov/32171429/
Lungenkarzinom|2.1|2022|Fleckenstein, Jochen|Hintergrund||Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21 (4):581-592|https://pubmed.ncbi.nlm.nih.gov/32171429/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Empfehlung|ERSTAUTOR|Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21 (4):581-592|https://pubmed.ncbi.nlm.nih.gov/32171429/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Hintergrund|ERSTAUTOR|Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21 (4):581-592|https://pubmed.ncbi.nlm.nih.gov/32171429/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung|LETZTAUTOR|Guberina M, Darwiche K, Hautzel H, Ploenes T, Pöttgen C, Guberina N, et al. Impact of EBUS-TBNA in addition to [. Eur J Nucl Med Mol Imaging. 2021;48 (9):2894-2903|https://pubmed.ncbi.nlm.nih.gov/33547554/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund|LETZTAUTOR|Guberina M, Darwiche K, Hautzel H, Ploenes T, Pöttgen C, Guberina N, et al. Impact of EBUS-TBNA in addition to [. Eur J Nucl Med Mol Imaging. 2021;48 (9):2894-2903|https://pubmed.ncbi.nlm.nih.gov/33547554/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Empfehlung|ERSTAUTOR|Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018;127 (1):1-5|https://pubmed.ncbi.nlm.nih.gov/29605476/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Hintergrund|ERSTAUTOR|Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018;127 (1):1-5|https://pubmed.ncbi.nlm.nih.gov/29605476/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung||Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280 ():163-175|https://pubmed.ncbi.nlm.nih.gov/30661849/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund||Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280 ():163-175|https://pubmed.ncbi.nlm.nih.gov/30661849/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung||Huber RM, Reck M, Thomas M. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. Eur Respir J. 2013;42 (4):1119-33|https://pubmed.ncbi.nlm.nih.gov/23429914/
Lungenkarzinom|2.1|2022|Thomas, Michael|Empfehlung|LETZTAUTOR|Huber RM, Reck M, Thomas M. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. Eur Respir J. 2013;42 (4):1119-33|https://pubmed.ncbi.nlm.nih.gov/23429914/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund||Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer. 2019;133 ():83-87|https://pubmed.ncbi.nlm.nih.gov/31200833/
Lungenkarzinom|2.1|2022|Tufman, Amanda|Hintergrund||Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer. 2019;133 ():83-87|https://pubmed.ncbi.nlm.nih.gov/31200833/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung||Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379 (24):2342-2350|https://pubmed.ncbi.nlm.nih.gov/30280658/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379 (24):2342-2350|https://pubmed.ncbi.nlm.nih.gov/30280658/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32 (35):4012-9|https://pubmed.ncbi.nlm.nih.gov/25385727/
Lungenkarzinom|2.1|2022|Schütte, Wolfgang|Hintergrund||von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32 (35):4012-9|https://pubmed.ncbi.nlm.nih.gov/25385727/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Haun MW, Estel S, Rücker G, Friederich HC, Villalobos M, Thomas M, et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev. 2017;6 ():CD011129|https://pubmed.ncbi.nlm.nih.gov/28603881/
Lungenkarzinom|2.1|2022|Baysal, Barbara|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Blum, Torsten Gerriet|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Dickgreber, Nikolas|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Eberhardt, Wilfried|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Eggeling, Stephan|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Flentje, Michael|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Gütz, Sylvia|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Hellwig, Dirk|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Kraus, Thomas|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Nowak, Dennis|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Passlick, Bernward|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Rübe, Christian|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Schütte, Wolfgang|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Serke, Monika|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Stoelben, Erich|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Wolf, Martin|Hintergrund||Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018;13 (9):1248-1268|https://pubmed.ncbi.nlm.nih.gov/29885479/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Empfehlung||Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with . N Engl J Med. 2021;384 (25):2371-2381|https://pubmed.ncbi.nlm.nih.gov/34096690/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund||Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with . N Engl J Med. 2021;384 (25):2371-2381|https://pubmed.ncbi.nlm.nih.gov/34096690/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Empfehlung||Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383 (14):1328-1339|https://pubmed.ncbi.nlm.nih.gov/32997907/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Hintergrund||Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383 (14):1328-1339|https://pubmed.ncbi.nlm.nih.gov/32997907/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung|LETZTAUTOR|Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33 (35):4194-201|https://pubmed.ncbi.nlm.nih.gov/26527789/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund|LETZTAUTOR|Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33 (35):4194-201|https://pubmed.ncbi.nlm.nih.gov/26527789/
Lungenkarzinom|2.1|2022|Büttner, Reinhard|Empfehlung||Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Büttner, Reinhard|Hintergrund||Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Sebastian, Martin|Empfehlung||Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Sebastian, Martin|Hintergrund||Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Serke, Monika|Empfehlung||Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Serke, Monika|Hintergrund||Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Empfehlung|LETZTAUTOR|Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund|LETZTAUTOR|Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29 (10):2068-2075|https://pubmed.ncbi.nlm.nih.gov/30165392/
Lungenkarzinom|2.1|2022|Büttner, Reinhard|Empfehlung||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Büttner, Reinhard|Hintergrund||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Grohé, Christian|Empfehlung||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Grohé, Christian|Hintergrund||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Sebastian, Martin|Empfehlung||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Sebastian, Martin|Hintergrund||Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Empfehlung|LETZTAUTOR|Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund|LETZTAUTOR|Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/
Lungenkarzinom|2.1|2022|Büttner, Reinhard|Hintergrund||Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget. 2015;6 (2):1315-26|https://pubmed.ncbi.nlm.nih.gov/25473901/
Lungenkarzinom|2.1|2022|Serke, Monika|Hintergrund||Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget. 2015;6 (2):1315-26|https://pubmed.ncbi.nlm.nih.gov/25473901/
Lungenkarzinom|2.1|2022|Stoelben, Erich|Hintergrund||Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget. 2015;6 (2):1315-26|https://pubmed.ncbi.nlm.nih.gov/25473901/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund|LETZTAUTOR|Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget. 2015;6 (2):1315-26|https://pubmed.ncbi.nlm.nih.gov/25473901/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund||Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, et al. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. J Thorac Oncol. 2017;12 (1):54-64|https://pubmed.ncbi.nlm.nih.gov/27575422/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund||Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of Selpercatinib in . N Engl J Med. 2020;383 (9):813-824|https://pubmed.ncbi.nlm.nih.gov/32846060/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Empfehlung||Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in Non-Small-Cell Lung Cancer with . N Engl J Med. 2020;383 (10):931-943|https://pubmed.ncbi.nlm.nih.gov/32469185/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Empfehlung||Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in Non-Small-Cell Lung Cancer with . N Engl J Med. 2020;383 (10):931-943|https://pubmed.ncbi.nlm.nih.gov/32469185/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Empfehlung||Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol. 2015;10 (10):1451-7|https://pubmed.ncbi.nlm.nih.gov/26200454/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund||Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol. 2015;10 (10):1451-7|https://pubmed.ncbi.nlm.nih.gov/26200454/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Empfehlung||Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373 (8):726-36|https://pubmed.ncbi.nlm.nih.gov/26287849/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund||Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373 (8):726-36|https://pubmed.ncbi.nlm.nih.gov/26287849/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Hintergrund||Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23 (1):104-114|https://pubmed.ncbi.nlm.nih.gov/34919827/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Empfehlung||West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20 (7):924-937|https://pubmed.ncbi.nlm.nih.gov/31122901/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Hintergrund||West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20 (7):924-937|https://pubmed.ncbi.nlm.nih.gov/31122901/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund|ERSTAUTOR|Reck M, Wehler T, Orlandi F, Nogami N, Barone C, Moro-Sibilot D, et al. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38 (22):2530-2542|https://pubmed.ncbi.nlm.nih.gov/32459597/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung||Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381 (21):2020-2031|https://pubmed.ncbi.nlm.nih.gov/31562796/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381 (21):2020-2031|https://pubmed.ncbi.nlm.nih.gov/31562796/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung|LETZTAUTOR|Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22 (2):198-211|https://pubmed.ncbi.nlm.nih.gov/33476593/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund|LETZTAUTOR|Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22 (2):198-211|https://pubmed.ncbi.nlm.nih.gov/33476593/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund|ERSTAUTOR|Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021; ():JCO2100174|https://pubmed.ncbi.nlm.nih.gov/33872070/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376 (25):2415-2426|https://pubmed.ncbi.nlm.nih.gov/28636851/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Empfehlung|ERSTAUTOR|Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund|ERSTAUTOR|Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Empfehlung||Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Hintergrund||Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Empfehlung||De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124 (1):1-10|https://pubmed.ncbi.nlm.nih.gov/28666551/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund||De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124 (1):1-10|https://pubmed.ncbi.nlm.nih.gov/28666551/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Empfehlung||De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124 (1):1-10|https://pubmed.ncbi.nlm.nih.gov/28666551/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Hintergrund||De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124 (1):1-10|https://pubmed.ncbi.nlm.nih.gov/28666551/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund|ERSTAUTOR|Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, et al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 2018;102 ():23-30|https://pubmed.ncbi.nlm.nih.gov/30103096/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung|ERSTAUTOR|Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019;37 (7):537-546|https://pubmed.ncbi.nlm.nih.gov/30620668/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Empfehlung||De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28 (36):5301-10|https://pubmed.ncbi.nlm.nih.gov/21079134/
Lungenkarzinom|2.1|2022|Nestle, Ursula|Hintergrund||De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28 (36):5301-10|https://pubmed.ncbi.nlm.nih.gov/21079134/
Lungenkarzinom|2.1|2022|Passlick, Bernward|Empfehlung||Palade E, Passlick B, Osei-Agyemang T, Günter J, Wiesemann S. Video-assisted vs open mediastinal lymphadenectomy for Stage I non-small-cell lung cancer: results of a prospective randomized trial. Eur J Cardiothorac Surg. 2013;44 (2):244-9; discussion 249|https://pubmed.ncbi.nlm.nih.gov/23295451/
Lungenkarzinom|2.1|2022|Passlick, Bernward|Hintergrund||Palade E, Passlick B, Osei-Agyemang T, Günter J, Wiesemann S. Video-assisted vs open mediastinal lymphadenectomy for Stage I non-small-cell lung cancer: results of a prospective randomized trial. Eur J Cardiothorac Surg. 2013;44 (2):244-9; discussion 249|https://pubmed.ncbi.nlm.nih.gov/23295451/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund||Schanne DH, Heitmann J, Guckenberger M, Andratschke NHJ. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature. Cancer Treat Rev. 2019;80 ():101892|https://pubmed.ncbi.nlm.nih.gov/31522079/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund||Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019;14 (12):2109-2119|https://pubmed.ncbi.nlm.nih.gov/31398540/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019;14 (12):2109-2119|https://pubmed.ncbi.nlm.nih.gov/31398540/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund|LETZTAUTOR|Hörner-Rieber J, Bernhardt D, Blanck O, Duma M, Eich HT, Gerum S, et al. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. Clin Lung Cancer. 2019;20 (6):e667-e677|https://pubmed.ncbi.nlm.nih.gov/31327644/
Lungenkarzinom|2.1|2022|Flentje, Michael|Hintergrund||Klement RJ, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, et al. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol. 2018;127 (2):246-252|https://pubmed.ncbi.nlm.nih.gov/29510865/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund|LETZTAUTOR|Klement RJ, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, et al. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol. 2018;127 (2):246-252|https://pubmed.ncbi.nlm.nih.gov/29510865/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund||Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18 (1):283|https://pubmed.ncbi.nlm.nih.gov/29534687/
Lungenkarzinom|2.1|2022|Waller, Cornelius|Hintergrund||Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7 (9):1432-9|https://pubmed.ncbi.nlm.nih.gov/22895140/
Lungenkarzinom|2.1|2022|Wolf, Martin|Hintergrund|LETZTAUTOR|Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7 (9):1432-9|https://pubmed.ncbi.nlm.nih.gov/22895140/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379 (23):2220-2229|https://pubmed.ncbi.nlm.nih.gov/30280641/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Hintergrund||Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394 (10212):1929-1939|https://pubmed.ncbi.nlm.nih.gov/31590988/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund|ERSTAUTOR|Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016;34 (31):3740-3748|https://pubmed.ncbi.nlm.nih.gov/27458307/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016;34 (31):3740-3748|https://pubmed.ncbi.nlm.nih.gov/27458307/
Lungenkarzinom|2.1|2022|Kraywinkel, Klaus|Hintergrund|LETZTAUTOR|Hoebel J, Kroll LE, Fiebig J, Lampert T, Katalinic A, Barnes B, et al. Socioeconomic Inequalities in Total and Site-Specific Cancer Incidence in Germany: A Population-Based Registry Study. Front Oncol. 2018;8 ():402|https://pubmed.ncbi.nlm.nih.gov/30319967/
Lungenkarzinom|2.1|2022|Passlick, Bernward|Empfehlung||De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45 (5):787-98|https://pubmed.ncbi.nlm.nih.gov/24578407/
Lungenkarzinom|2.1|2022|Passlick, Bernward|Hintergrund||De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45 (5):787-98|https://pubmed.ncbi.nlm.nih.gov/24578407/
Lungenkarzinom|2.1|2022|Passlick, Bernward|Hintergrund||De Leyn P, Lardinois D, Van Schil P, Rami-Porta R, Passlick B, Zielinski M, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol. 2007;2 (4):357-61|https://pubmed.ncbi.nlm.nih.gov/17409811/
Lungenkarzinom|2.1|2022|Hoffmann, Hans|Empfehlung||Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26 (8):1573-88|https://pubmed.ncbi.nlm.nih.gov/25897013/
Lungenkarzinom|2.1|2022|Hoffmann, Hans|Hintergrund||Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26 (8):1573-88|https://pubmed.ncbi.nlm.nih.gov/25897013/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Empfehlung||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Empfehlung||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Reinmuth, Niels|Hintergrund||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Sebastian, Martin|Empfehlung||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Sebastian, Martin|Hintergrund||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Serke, Monika|Empfehlung||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Serke, Monika|Hintergrund||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Thomas, Michael|Empfehlung||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund||Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Empfehlung||Eberhardt WE, Gauler TC, Lepechoux C, Stamatis G, Bildat S, Krbek T, et al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Lung Cancer. 2013;82 (1):83-9|https://pubmed.ncbi.nlm.nih.gov/23957964/
Lungenkarzinom|2.1|2022|Stuschke, Martin|Hintergrund||Eberhardt WE, Gauler TC, Lepechoux C, Stamatis G, Bildat S, Krbek T, et al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Lung Cancer. 2013;82 (1):83-9|https://pubmed.ncbi.nlm.nih.gov/23957964/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Empfehlung||Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/
Lungenkarzinom|2.1|2022|Griesinger, Frank|Hintergrund||Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/
Lungenkarzinom|2.1|2022|Hoffmann, Hans|Empfehlung||Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/
Lungenkarzinom|2.1|2022|Hoffmann, Hans|Hintergrund||Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/
Lungenkarzinom|2.1|2022|Thomas, Michael|Empfehlung|LETZTAUTOR|Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/
Lungenkarzinom|2.1|2022|Thomas, Michael|Hintergrund|LETZTAUTOR|Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/
Lungenkarzinom|2.1|2022|Reck, Martin|Empfehlung||Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378 (22):2078-2092|https://pubmed.ncbi.nlm.nih.gov/29658856/
Lungenkarzinom|2.1|2022|Reck, Martin|Hintergrund||Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378 (22):2078-2092|https://pubmed.ncbi.nlm.nih.gov/29658856/
Lungenkarzinom|2.1|2022|Hoffmann, Hans|Empfehlung||Edwards JG, Chansky K, Van Schil P, Nicholson AG, Boubia S, Brambilla E, et al. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol. 2020;15 (3):344-359|https://pubmed.ncbi.nlm.nih.gov/31731014/
Lungenkarzinom|2.1|2022|Hoffmann, Hans|Hintergrund||Edwards JG, Chansky K, Van Schil P, Nicholson AG, Boubia S, Brambilla E, et al. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol. 2020;15 (3):344-359|https://pubmed.ncbi.nlm.nih.gov/31731014/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Empfehlung||Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012;7 (9):1382-93|https://pubmed.ncbi.nlm.nih.gov/22843086/
Lungenkarzinom|2.1|2022|Guckenberger, Matthias|Hintergrund||Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012;7 (9):1382-93|https://pubmed.ncbi.nlm.nih.gov/22843086/
Lungenkarzinom|2.1|2022|Wolf, Jürgen|Hintergrund||Gärtner J, Daun M, Wolf J, von Bergwelt-Baildon M, Hallek M. Early Palliative Care: Pro, but Please Be Precise!. Oncol Res Treat. 2019;42 (1-2):11-18|https://pubmed.ncbi.nlm.nih.gov/30685764/